Novel 3(rd) generation humanized type IICD20 antibody with glycoengineered fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction.

@inproceedings{Umaa2006Novel3G,
  title={Novel 3(rd) generation humanized type IICD20 antibody with glycoengineered fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction.},
  author={Pablo Uma{\~n}a and Ekkehard Moessner and Peter Bruenker and Gabriele Unsin and Ursula Puentener and Tobias Suter and Roger Grau and Carla Schmidt and Christian Gerdes and Adam Nopora and Monika Patre and Samuel Moser and Peter Sondermann and Luise M C Wheat and Martin J S Dyer and Sibrand Poppema and Pamela Strein and Thomas Friess and Christian Klein},
  year={2006}
}
Background: Treatment of B-cell non-Hodgkin lymphoma (NHL) with antibodies targeting CD20 in conjunction with combination chemotherapy is standard clinical practice. Two different types of CD20 MAb differing significantly in their mode of CD20 binding and biological activities have been identified (Cragg and Glennie. Blood103: 2738–2743, 2004): type I antibodies, as rituximab, are potent in complement mediated cytotoxicity, whereas type II antibodies, as tositumomab, effectively initiate target… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

[Antibodies: better knowledge for a better use].

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Immunosuppressive monoclonal antibodies: current and next generation.

  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2011